Current concepts for the reduction of mortality in severe sepsis and multiple organ failure

被引:0
作者
Sablotzki, A
Klöss, T
Radke, J
Grond, S
机构
[1] Univ Halle Wittenberg, Klin Anasthesiol & Operat Intens Med, D-06120 Halle An Der Saale, Germany
[2] Allgemeines Krankenhaus, Abt Anasthesie & Operat Intens Med, Hamburg, Germany
来源
ANASTHESIOLOGIE & INTENSIVMEDIZIN | 2003年 / 44卷 / 04期
关键词
sepsis; mortality; multiple organ failure; drotrecogin alfa activated; corticosteroids insulin;
D O I
暂无
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
In the past few years, considerable progress has been made in the development of therapeutic concepts to reduce mortality in sepsis and septic shock. Some of these approaches attempt to modulate or interrupt the cascade effects of sepsis in order to stop the causes of multiple organ failure (e.g. TNF-alpha antibodies, high-flow haemofiltration, antielastases, modulators of coagulation), while others focus on the improvement of ICU management of organ dysfunction. This review reports about four new concepts, presented on the 32nd Congress of the Society of Critical Care Medicine (SCCM, San Antonio/Texas, USA, 28(th) January - 2(nd) February 2003) as very apt and promising new interventions for the ICU setting to decrease the unacceptably high mortality rate in patients with severe sepsis.
引用
收藏
页码:264 / +
页数:8
相关论文
共 28 条
  • [1] ANGUS D, 2003, GLOB MED C VORTR 32
  • [2] Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
    Angus, DC
    Linde-Zwirble, WT
    Lidicker, J
    Clermont, G
    Carcillo, J
    Pinsky, MR
    [J]. CRITICAL CARE MEDICINE, 2001, 29 (07) : 1303 - 1310
  • [3] A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin
    Annane, D
    Sébille, V
    Troché, G
    Raphaël, JC
    Gajdos, P
    Bellissant, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (08): : 1038 - 1045
  • [4] Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock
    Annane, D
    Sébille, V
    Charpentier, C
    Bollaert, PE
    François, B
    Korach, JM
    Capellier, G
    Cohen, Y
    Azoulay, E
    Troché, G
    Chaumet-Riffaut, P
    Bellissant, E
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (07): : 862 - 871
  • [5] [Anonymous], 1988, LANCET, V2, P349
  • [6] [Anonymous], NATL VITAL STAT REPO
  • [7] MULTIPLE ORGAN FAILURE SYNDROME IN THE 1990S - SYSTEMIC INFLAMMATORY RESPONSE AND ORGAN DYSFUNCTION
    BEAL, AL
    CERRA, FB
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (03): : 226 - 233
  • [8] Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard, GR
    Vincent, JL
    Laterre, P
    LaRosa, SP
    Dhainaut, JF
    Lopez-Rodriguez, A
    Steingrub, JS
    Garber, GE
    Helterbrand, JD
    Ely, EW
    Fisher, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) : 699 - 709
  • [9] BERNARD GR, 2003, GLOB MED C VORTR 32
  • [10] Reversal of late septic shock with supraphysiologic doses of hydrocortisone
    Bollaert, PE
    Charpentier, C
    Levy, B
    Debouverie, M
    Audibert, G
    Larcan, A
    [J]. CRITICAL CARE MEDICINE, 1998, 26 (04) : 645 - 650